ANAB AnaptysBio, Inc
AnaptysBio, Inc (ANAB) is expected to report earnings on August 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on May 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About AnaptysBio, Inc
AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.
Sector
Healthcare
Industry
Biotechnology